NL-OMON39595已完成不适用
Determination of minimum and non-provoking doses of soy protein in soy allergic individuals - Determination of minimum and non provoking doses of soy
FARRP; Food Allergy Research and Resource Program, Department of Food Science & Technology, University of Nebraska0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Convincing clinical history of a Type I allergic reaction caused by eating soybeans or soy flour
- •2) Positive skin prick test to the extract of soy flour used to make the oral challenges AND positive specific immunoglobulin E (IgE) to soy (CAP-RAST, Pharmacia Uppsala, Sweden). Subjects should also be skin prick tested with a commercial soy extract.
- •3) Adults (18-70 years)
排除标准
- •1) Subjects with allergy to wheat
- •2) Pregnancy
研究者
相似试验
撤回
不适用
Determination of Minimum and Non-provoking Doses of Soy Protein in Soy Allergic Individualsfood allergysoy allergy10001708NL-OMON34810FARRP: Food Allergy Research and Resource Program5
招募中
1 期
Dose finding study for deciding the optimal dose of fluorescein during probe based confocal endomicroscopyJPRN-UMIN000027696ational Cancer Center Hospital24
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-SEInstitut de Recherches Internationales Servier90
进行中（未招募）
1 期
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-ESab Servier116